Results 221 to 230 of about 168,097 (250)
Some of the next articles are maybe not open access.

Heart Failure With Preserved Ejection Fraction: A Review.

Journal of the American Medical Association (JAMA), 2023
Importance Heart failure with preserved ejection fraction (HFpEF), defined as HF with an EF of 50% or higher at diagnosis, affects approximately 3 million people in the US and up to 32 million people worldwide.
M. Redfield, B. Borlaug
semanticscholar   +1 more source

Obesity and heart failure with preserved ejection fraction: new insights and pathophysiologic targets.

Cardiovascular Research, 2022
Obesity and heart failure (HF) with preserved ejection fraction (HFpEF) represent two intermingling epidemics driving perhaps the greatest unmet health problem in cardiovascular medicine in the 21st century. Many patients with HFpEF are either overweight
B. Borlaug   +5 more
semanticscholar   +1 more source

Haemodynamic and metabolic phenotyping of patients with aortic stenosis and preserved ejection fraction: A specific phenotype of heart failure with preserved ejection fraction?

European Journal of Heart Failure, 2023
Degenerative aortic valve stenosis with preserved ejection fraction (ASpEF) and heart failure with preserved ejection fraction (HFpEF) display intriguing similarities. This study aimed to provide a non‐invasive, comparative analysis of ASpEF versus HFpEF
N. De Biase   +12 more
semanticscholar   +1 more source

Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.

New England Journal of Medicine
BACKGROUND Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss, but data ...
Milton Packer   +12 more
semanticscholar   +1 more source

Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.

New England Journal of Medicine
BACKGROUND Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and mildly reduced or preserved ejection fraction ...
Scott D. Solomon   +58 more
semanticscholar   +1 more source

Heart failure with preserved ejection fraction.

New England Journal of Medicine, 2006
A. Ahmed, J. Fleg, M. Gheorghiade
semanticscholar   +1 more source

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Ca-A Cancer Journal for Clinicians, 2021
Hyuna Sung   +2 more
exaly  

Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial

Nature Network Boston, 2021
G. Lewis   +16 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy